{"entity": "researcher", "timestamp": "2026-08-22T06:56:29.903Z", "family": "Simin", "given": "Johanna", "initials": "J", "orcid": "0000-0003-1611-139X", "affiliations": ["Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Reseaarch (CTMR), Stockholm, Sweden.", "Science for Life Laboratory (SciLifeLab), Stockholm, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/cd509478f65a4271acd1a2889da10cb4.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/cd509478f65a4271acd1a2889da10cb4"}}, "publications": [{"entity": "publication", "iuid": "e7a9021ea28a460f8969a7b70cf99562", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/e7a9021ea28a460f8969a7b70cf99562.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/e7a9021ea28a460f8969a7b70cf99562"}}, "title": "Association between menopausal hormone therapy use and mortality risk: a Swedish population-based matched cohort study.", "authors": [{"family": "Simin", "given": "Johanna", "initials": "J", "orcid": "0000-0003-1611-139X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cd509478f65a4271acd1a2889da10cb4.json"}}, {"family": "Khodir", "given": "Habiba", "initials": "H"}, {"family": "Fornes", "given": "Romina", "initials": "R"}, {"family": "Tamimi", "given": "Rulla M", "initials": "RM"}, {"family": "Brusselaers", "given": "Nele", "initials": "N", "orcid": "0000-0003-0137-447X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/70d0a6a2f4eb4272be4865e7e369c0e9.json"}}], "type": "journal article", "published": "2022-05-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "volume": "61", "issue": "5", "pages": "632-640", "issn-l": "0284-186X"}, "abstract": "The net effect of menopausal hormone therapy on the risk of death is understudied, and current evidence is conflicting. Our aim was to investigate the association between menopausal hormones and risk of all-cause, cardiovascular, and cancer-specific mortality, based on the Swedish Prescribed Drug Registry and National Patient Registry.\n\nThis Swedish population-based matched cohort study included all women, 40 years or older, who had received at least one prescription of systemic menopausal hormone therapy between 2005-2014 (n = 290,186), group level matched 1:3 to non-users (n = 870,165). Multivariable conditional logistic regression models estimated the relative risk of all-cause and cause-specific mortality, adjusting for several clinical factors and comorbidities.\n\nEver-use of menopausal hormones was associated with a slightly lower overall odds of all-cause (OR = 0.97, 95%CI 0.95-0.98) and cardiovascular (OR = 0.97, 95%CI 0.95-0.99) mortality, whilst 30% lower overall odds of cancer-related mortality (OR = 0.70, 95%CI 0.68-0.72) was shown. The odds of all-cause and cancer-related mortality were consistently reduced among women who began menopausal hormone therapy \u226460 years, whereas the association with cardiovascular mortality was inconsistent. In contrast, oestrogen-only therapy was associated with elevated odds of all-cause (OR = 1.14, 95%CI 1.11-1.16) and cardiovascular mortality (OR = 1.04, 95%CI 1.01-1.06) among women who began treatment at \u226570 years. Among current users, oestrogen-only therapy was associated with higher odds of all-cause (OR = 1.48, 95%CI 1.44-1.52) and cardiovascular mortality (OR = 1.24, 95%CI 1.20-1.28), whereas past use of oestrogen-only therapy suggested lower odds of mortality.\n\nOur generalisable data suggest that early menopausal hormone treatment initiation does not increase the odds of mortality. However, the role of oestrogens in particularly cardiovascular mortality remains to be investigated.", "doi": "10.1080/0284186X.2022.2033316", "pmid": "35129052", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-21T12:04:30.617Z", "modified": "2026-08-21T12:04:30.656Z"}, {"entity": "publication", "iuid": "f2310adeb69048198505702218eab5ae", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f2310adeb69048198505702218eab5ae.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f2310adeb69048198505702218eab5ae"}}, "title": "Prediagnostic use of estrogen-only therapy is associated with improved colorectal cancer survival in menopausal women: a Swedish population-based cohort study.", "authors": [{"family": "Simin", "given": "Johanna", "initials": "J", "orcid": "0000-0003-1611-139X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cd509478f65a4271acd1a2889da10cb4.json"}}, {"family": "Liu", "given": "Qing", "initials": "Q"}, {"family": "Wang", "given": "Xinchen", "initials": "X"}, {"family": "Fall", "given": "Katja", "initials": "K"}, {"family": "Williams", "given": "Cecilia", "initials": "C"}, {"family": "Callens", "given": "Steven", "initials": "S"}, {"family": "Engstrand", "given": "Lars", "initials": "L"}, {"family": "Brusselaers", "given": "Nele", "initials": "N", "orcid": "0000-0003-0137-447X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/70d0a6a2f4eb4272be4865e7e369c0e9.json"}}], "type": "journal article", "published": "2021-07-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "volume": "60", "issue": "7", "pages": "881-887", "issn-l": "0284-186X"}, "abstract": "Menopausal hormone therapy (MHT) reduces the risk of developing colorectal cancer (CRC), yet it is largely unclear whether it could also influence survival in women with CRC. Therefore, we aimed to investigate the influence of prediagnostic MHT use on CRC-specific and all-cause mortality in women with CRC.\n\nThis nationwide nested cohort study, within a large population-based matched cohort, included all women diagnosed with incident CRC between January 2006 and December 2012 (N = 7814). A total of 1529 women had received at least one dispensed prescription of systemic MHT before CRC diagnosis, and 6285 CRC women with CRC did not receive MHT during the study period, as ascertained from the Swedish Prescribed Drug Registry. Multivariable Cox regression models provided adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for CRC-specific mortality and all-cause mortality.\n\nPast use of prediagnostic estrogen-only therapy (E-MHT) was associated with lower CRC-specific (HR = 0.67, 95%CI 0.44-0.99) and all-cause mortality (HR = 0.68, 95%CI 0.59-0.93). However, all-cause mortality (HR = 1.23, 95%CI 1.02-1.48) was elevated among current prediagnostic E-MHT users who were 70+ years at diagnosis. Current estrogen combined progestin therapy (EP-MHT) was associated with higher CRC-specific mortality (HR = 1.61, 95%CI 1.06-2.44) in older women, but no association was shown for all-cause mortality.\n\nOur findings suggest that E-MHT, but not EP-MHT use, might be associated with improved CRC survival, indicating a potential role of estrogens in sex hormone-related cancers. However, association of MHT use with grade of cancer remains unclear.", "doi": "10.1080/0284186X.2021.1909747", "pmid": "33861686", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-20T09:34:31.594Z", "modified": "2026-08-21T09:28:05.289Z"}, {"entity": "publication", "iuid": "62fda3dd52cc41879536b28833a78136", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/62fda3dd52cc41879536b28833a78136.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/62fda3dd52cc41879536b28833a78136"}}, "title": "Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis.", "authors": [{"family": "Simin", "given": "Johanna", "initials": "J", "orcid": "0000-0003-1611-139X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cd509478f65a4271acd1a2889da10cb4.json"}}, {"family": "Fornes", "given": "Romina", "initials": "R"}, {"family": "Liu", "given": "Qing", "initials": "Q"}, {"family": "Olsen", "given": "Renate Slind", "initials": "RS"}, {"family": "Callens", "given": "Steven", "initials": "S"}, {"family": "Engstrand", "given": "Lars", "initials": "L"}, {"family": "Brusselaers", "given": "Nele", "initials": "N"}], "type": "journal article", "published": "2020-12-00", "journal": {"title": "Br. J. Cancer", "issn": "1532-1827", "volume": "123", "issue": "12", "pages": "1825-1832", "issn-l": "0007-0920"}, "abstract": "It is understudied whether the posed association of oral antibiotics with colorectal cancer (CRC) varies between antibiotic spectrums, colorectal continuum, and if a non-linear dose-dependent relationship is present.\n\nThree electronic databases and a trial platform were searched for all relevant studies, from inception until February 2020, without restrictions. Random-effects meta-analyses provided pooled effect-sizes (ES) with 95% confidence intervals (CI). Dose-response analyses modelling the relationship between number of days exposed to antibiotics and CRC risk were extended to non-linear multivariable random-effects models.\n\nOf 6483 identified publications ten were eligible, including 4.1 million individuals and over 73,550 CRC cases. The pooled CRC risk was increased among individuals who ever-used antibiotics (ES = 1.17, 95%CI 1.05-1.30), particularly for broad-spectrum antibiotics (ES = 1.70, 95%CI 1.26-2.30), but not for narrow-spectrum antibiotic (ES = 1.11, 95% 0.93-1.32). The dose-response analysis did not provide strong evidence of any particular dose-response association, and the risk patterns were rather similar for colon and rectal cancer.\n\nThe antibiotic use associated CRC risk seemingly differs between broad- and narrow-spectrum antibiotics, and possibly within the colorectal continuum. It remains unclear whether this association is causal, requiring more mechanistic studies and further clarification of drug-microbiome interactions.", "doi": "10.1038/s41416-020-01082-2", "pmid": "32968205", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7722751"}, {"db": "pii", "key": "10.1038/s41416-020-01082-2"}], "notes": [], "created": "2026-08-21T11:47:24.295Z", "modified": "2026-08-21T11:47:24.361Z"}, {"entity": "publication", "iuid": "196e1919e3244a08b6bc70b30638fc27", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/196e1919e3244a08b6bc70b30638fc27.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/196e1919e3244a08b6bc70b30638fc27"}}, "title": "Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.", "authors": [{"family": "Simin", "given": "Johanna", "initials": "J", "orcid": "0000-0003-1611-139X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cd509478f65a4271acd1a2889da10cb4.json"}}, {"family": "Tamimi", "given": "Rulla M", "initials": "RM"}, {"family": "Callens", "given": "Steven", "initials": "S"}, {"family": "Engstrand", "given": "Lars", "initials": "L"}, {"family": "Brusselaers", "given": "Nele", "initials": "N", "orcid": "0000-0003-0137-447X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/70d0a6a2f4eb4272be4865e7e369c0e9.json"}}], "type": "journal article", "published": "2020-07-01", "journal": {"title": "Int. J. Cancer", "issn": "1097-0215", "volume": "147", "issue": "1", "pages": "33-44", "issn-l": "0020-7136"}, "abstract": "Although menopausal hormone therapy (MHT) seemingly increases the risk of ovarian cancer, evidence is insufficient whether the risk varies between various MHT formulations, regimens and administration modes. With the aim of filling these knowledge gaps, we investigated the effect of different MHT treatment options on the risk of ovarian cancer. This prospective Swedish population-based matched-cohort study included all women \u226540 years having used systemic MHT between 2005 and 2012 (288,950 ever-users), group-level matched (1:3) to 866,546 nonusers. MHT use was ascertained from the Swedish Prescribed Drug Registry and data was linked to several national health data registries. Multivariable conditional logistic regression provided odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for parity, and comorbidities. Current EP-MHT use was associated with a modestly increased risk of ovarian cancer (OR = 1.38, 95% CI 1.18-1.62), while no consistent risk was found among past users (OR = 1.00, 95% CI 0.84-1.18). Current continuous testosterone derived (OR = 1.50, 95% CI 1.15-1.96) regimens increased the risk whereas progesterone derived (OR = 1.48, 95% CI 1.00-2.21) regimens increased the risk marginally. Nonsignificant positive associations were observed for sequential regimens (OR = 1.87, 95% CI 0.70-5.08; OR = 1.54, 95% CI 0.96-2.47, respectively). An inverse relationship was observed for all E-MHT use (OR = 0.25, 95% CI 0.22-0.29), but this association might partly be explained by underreporting of oophorectomies or tubal ligations. Current cutaneous EP-MHT (OR = 1.28, 95% CI 0.81-2.02) suggested a possibly lower risk than oral MHT (OR = 1.48, 95% CI 1.25-1.75). In conclusion EP-MHT, notably continuous regimens, were associated with a modestly increased risk of ovarian cancer. The role of E-MHT requires further clarification.", "doi": "10.1002/ijc.32706", "pmid": "31584190", "labels": [], "xrefs": [], "notes": [], "created": "2026-08-21T11:02:34.806Z", "modified": "2026-08-21T11:02:34.878Z"}]}